WACKER BIOTECH is “THE MICROBIAL CDMO” – your partner of choice for process development and contract manufacturing of biopharmaceuticals (proteins, vaccines, live microbial products, plasmid DNA (pDNA)) using microbial hosts. Additionally, WACKER BIOTECH provides R&D and GMP manufacturing services for advanced therapies as a one-stop-shop: from the production of plasmid and template DNA as starting material for mRNA through the IVT of mRNA and LNP formulation, the nucleic acid expertise of Wacker Biotech combined with the lipid expertise of our partner CordenPharma ensures the best possible results for each of our client’s mRNA-focused projects. WACKER BIOTECH’s integrated service portfolio covers molecular biology, process / analytical development as well as GMP manufacturing of biologics for clinical and commercial supply. WACKER BIOTECH operates four state-of-the-art GMP facilities located in the U.S., Germany and The Netherlands. Manufacturing lines are equipped with stainless steel fermentation vessels from 350 to 1500 liter as well as single-use bioreactors. Matching primary recovery, downstream and Fill & Finish capabilities are available to suit various clients’ needs across the development path (BSL 1 and 2). Additionally, a GMP cell-bank suite enables independent cell-bank production and storage capacity for client cell banks. In 2022 the German government selected Wacker Biotech and CordenPharma as joint bidders for the stand-by production of vaccines based on mRNA. Therefore, WACKER is now building a state-of-the-art mRNA competence and manufacturing center at its existing Halle, Germany site to complement its other existing sites in Jena, Germany, Amsterdam, the Netherlands and San Diego, California. The new capabilities at Wacker Biotech Halle will support end-to-end manufacturing of plasmid DNA, mRNA and LNP formulation under one roof. WACKER BIOTECH holds biomanufacturing certificates from the relevant authorities for all sites and follows the ICH Q7A guidelines for GMP-compliant production of biologics. The GMP production facilities in the Netherlands and Germany are approved by the EMA, U.S. FDA and/or ANVISA for commercial manufacturing. The WACKER BIOTECH U.S. site is currently preparing for a U.S. FDA inspection. Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. are wholly-owned subsidiaries of Munich-based Wacker Chemie AG. | WACKER BIOTECH is the CDMO partner of choice for process development and manufacturing of biopharmaceuticals (therapeutic proteins, vaccines, live biotherapeutic products) based on microbial systems and for the entire manufacturing chain of pDNA, mRNA and lipid nanoparticle formulations. Our clients benefit from our decades of experience in complex protein-based therapeutics, vaccines, and specialty chemicals sectors, including partnering with the German government to respond to the Covid-19 pandemic. WACKER BIOTECH operates five state-of-the-art GMP facilities located in the U.S., Germany and The Netherlands. Manufacturing lines are equipped with stainless steel fermentation vessels from 350 to 1500 liter as well as single-use bioreactors. Matching primary recovery, downstream and Fill & Finish capabilities are available to suit various clients’ needs across the development path (BSL 1 and 2). WACKER BIOTECH provides R&D and GMP manufacturing services for advanced therapies as a one-stop-shop: from the production of plasmid and template DNA as starting material for mRNA through the IVT of mRNA and LNP formulation, the nucleic acid expertise of Wacker Biotech combined with the lipid expertise of our partner ensures the best possible results for each of our client’s mRNA-focused projects. In Amsterdam, NL, we jump-started mRNA manufacturing during the COVID-19 pandemic, making us a leading CDMO with hands-on GMP manufacturing experience of mRNA-based therapies, including validation GMP runs. With the addition of another cutting-edge competence center for mRNA actives in Halle, Germany, we have increased our RNA product manufacturing and LNP formulation capacity. In this dynamic field of advanced therapies, you will benefit from experienced, reputable partners validated by the German government. In close collaboration with universities and research institutions, WACKER’s corporate R&D team of over 200 researchers continuously develops new production platforms and technologies for all types of biopharmaceuticals, including pDNA, mRNA and LNPs. Competitive, outstanding solutions are our trademarks. Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. are wholly-owned subsidiaries of Munich-based Wacker Chemie AG. | Wacker Biotech is the expert biologics CDMO partner for process development and manufacturing of advanced therapies and vaccines, as well as live microbial products and recombinant proteins based on microbial systems. Our nucleic acid-based capabilities span the full manufacturing value chain, from the production of plasmid and template DNA as a starting material for mRNA through the IVT of mRNA to lipid nanoparticle (LNP) formulation. We have the capability to produce at diverse scales up to 1500 L and recently quadrupled our mRNA production capacity with the completion of a new mRNA competence center in Halle, Germany. In Wacker Biotech, you have a flexible partner delivering science-driven solutions and guidance from concept to commercialization. We operate five GMP manufacturing facilities in Germany (Halle and Jena), the Netherlands (Amsterdam) and the US (San Diego). Complementing our bioprocess development and manufacturing experts at these four sites is a team of dedicated research scientists leading continuous innovations and collaborations at our parent company’s R&D hub in Munich, Germany. Wacker Biotech is wholly owned by Munich-based Wacker Chemie AG, a publicly traded company founded in 1914 that pioneered some of the 20th century’s leading chemistry advances. We have 30+ years of experience developing biologics to advance human and animal health. | Wacker Biotech is the expert biologics CDMO partner for process development and manufacturing of advanced therapies and vaccines, as well as live microbial products and recombinant proteins based on microbial systems. Our nucleic acid-based capabilities span the full manufacturing value chain, from the production of plasmid DNA as a starting material for RNA, to the IVT of RNA, to lipid nanoparticle (LNP) formulation. We also produce >97% supercoiled plasmids for AAV and LV delivery, and for direct application. In Wacker Biotech, you have a flexible partner delivering science-driven solutions and guidance from concept to commercialization. Our global footprint encompasses five GMP manufacturing facilities in Germany (Halle and Jena), the Netherlands (Amsterdam) and USA (San Diego), able to produce at diverse R&D, HQ and GMP grades, with scale-up to 1500 L. Complementing our bioprocess development and manufacturing experts at these sites is a team of dedicated research scientists leading continuous innovations and collaborations, and also providing nucleic acid contract research services, at our parent company’s R&D hub in Munich, Germany. Wacker Biotech is wholly owned by Munich-based Wacker Chemie AG, a publicly traded company founded in 1914 that pioneered some of the 20th century’s leading biochemistry advances. We have 30+ years of experience manufacturing biologics to advance human and animal health.
Viruj Group
Viruj Group was established in 2014 by a group of young & experienced professionals with the specific objective to develop & produce complex, small to large volume, technology driven Intermediates/ API at competitive prices, thus providing the critical India advantage for a CRO/ NCE Molecules across the world. We are a partner for various Innovator companies to supply High Quality API’s /Intermediates & Fine chemicals at competitive prices Complying with Regulatory Requirements. Our Experienced R&D team – well qualified & equipped to develop most complex Intermediates/ APIs and expertise to handle wide range of chemical reactions. Manufacturing capabilities ranging from gram level to multiple ton lots. Strong Intellectual Property Management and Regulatory back up & Absolute assurance of best quality APIs. Expertise in the development of novel, non-infringing and cost-effective API’s Speed to market for customers and support the NCE / Dossier by time bound development. Timely delivery and prompt response to all queries of the customers CRO/CDMO – We intend to take up any projects in this area working closely with you team for small or big enquiries, we have a dedicated team working in this area. Flow Chemistry – Our process lab is established with a motto to make API / Intermediates and Fine Chemicals in Flow chemistry mode as far as the molecule permits, we have established few global business and making R&D/ Pilot scale modules and converting existing batch chemistry to flow chemistry way. We are ready to take up projects for any commercial scale products on Pharma/ Agro/Fine Chemicals space.
Vettiva Saúde Animal
Vettiva Animal Health is a biotech startup focused exclusively on Research and Development (R&D) and commercialization of innovative pharmaceuticals derived from Medical Cannabis. It is also the first company to formalizeclinical development of cannabidiol-based veterinary candidate therapies with the Brazilian Ministry of Agriculture, Livestock, and Supply (MAPA).
UK Pavilion
The (UK’s) Department for Business and Trade (DBT) helps businesses export, drives inward and outward investment, negotiates market access and trade deals, and champions free trade. We are an international economic department, responsible for: • supporting and encouraging UK businesses to drive sustainable international growth • ensuring the UK remains a leading destination for international investment • opening markets, moulding the trade environment with new and existing partners which is free and fair • using trade and investment to underpin the government’s agenda for a Global Britain and its ambitions for prosperity, stability and security worldwide. | The UK’s Department for Business and Trade supports international investment into the UK and UK businesses to grow and export. Whether you’re interested in clinical research for innovative products, working with the UK’s world-leading universities, SMEs and spin outs, leveraging our globally-unique datasets or manufacturing complex products at pace and scale, the UK has a strong offer spanning Northern Ireland, Scotland and Wales and would like to work with you. We are joined by 16 inspired, innovative and international UK co-exhibitors eager to connect with you. | The UK’s Department for Business and Trade supports international investment into the UK and UK businesses to grow and export. Whether you’re interested in clinical research for innovative products, working with the UK’s world-leading universities, SMEs and spin outs, leveraging our globally-unique datasets or manufacturing complex products at pace and scale, the UK has a strong offer spanning Northern Ireland, Scotland, Wales and England and would like to work with you. This year, we are joined by 22 UK co-exhibitors eager to connect with you. | The Advanced Propulsion Centre (APC) is the organisation that pulls together exhibitors on the UK Pavilion who have advanced new technology and are looking for partner organisations to sell to or develop this technology with. The APC exists to ensure the UK remains competitive in the research, development and production of low emission technologies. Through our team of specialists we introduce those with good ideas to those who can take them to market, supporting through mentoring and providing access to funding. We are delivering a 10 year programme, launched in 2013. Born out of the collaboration between UK Government and industry, our organisation aims to save 50 million tonnes of CO2, safeguard or create 30,000 jobs in the UK and make £1 billion of match funding available to research and develop low emission propulsion technologies in the UK. | The Advanced Propulsion Centre UK (APC) collaborates with UK government, the automotive industry, and academia to facilitate driving research and investment in zero-emission vehicle manufacturing. Established in 2013 and jointly funded by the Department for Business and Trade (DBT) and the automotive industry, the APC accelerates the technologies that support the transition to zero-emission vehicle manufacturing and towards a net-zero automotive supply chain in the UK. With a proven track record, the APC has facilitated funding for 354 low-carbon and zero-emission projects involving 614 partners. Working with companies of all sizes, this funding since 2013 is estimated to have helped create or safeguard over 59,000 jobs in the UK. The technologies and products are projected to save over 425 million tonnes of CO2. The APC is committed to sustaining and enhancing the UK’s long-term automotive capabilities and investments through knowledge-sharing, collaboration, and innovation.
UDELA
Udelá is a regulatory consulting company. Udelá was created by a group of highly qualified professionals in the regulatory affairs field, with more than 15 years of experience, for medicines, medical devices, food, dietary supplements and cosmetics. Udelá is located in Mexico City, and has presence in Central and Latin America. Objectives – Provide technical and regulatory support, which accelerates the access of medicines, medical devices, food, dietary supplements and cosmetics on the market to improve the health of the population, through regulatory standard compliance and a build trust with regulatory agencies. – Bridge the knowledge gap of our clients in regulatory affairs to improve the communication with the regulatory agencies – Enhance processes of marketing authorization of medicines and medical devices (pre-marketing, registration and post marketing) to ease the access on the market and improve its maintenance – Active collaboration with our clients to generate better regulatory strategies to reduce timelines and optimize resources Services – Dossier compilation and evaluation o Medical Devices o New chemical entities/ New Molecules o Generics / Hybrids o Biotechnological products and Biosimilars o Vaccine o Biologics and blood derivative products – Design of regulatory strategies o Regulatory Due diligence o Feasibility studies for medicines and medical devices registration o Strategies for maintenance of existing and forthcoming products – Hosting & Testing services – Good manufacturing practices / License – Advertising – Translations – KOL feedback | At Udelá, we empower healthcare companies—whether local or international, emerging or established—to enter and expand in the complex markets of Mexico and Latin America. With over 5 years of experience, we specialize in regulatory intelligence, market entry strategies, and end-to-end support for pharmaceutical products, biotechnology, medical devices, cosmetics, food supplements, and more. We understand that navigating the ever-evolving regulatory frameworks of Latin American countries can be overwhelming if not approached strategically. That’s where we come in. Our multidisciplinary team of consultants combines in-depth knowledge of regional regulatory environments with strategic execution capabilities. We act with precision, pragmatism, and agility to deliver timely and compliant market access solutions. Our key services include: Regulatory and strategic consulting for healthcare products Legal representation and in-country regulatory agent services Warehousing and distribution infrastructure compliant with national regulations With headquarters in Mexico City and operations in Colombia, Brazil, Chile, Perú, Ecuador, Uruguay, Paraguay, Bolivia, Argentina and Central America, we offer both local expertise and regional reach. Whether you’re launching a generic, innovative, or biologic product—or seeking to expand your presence across LATAM—Udelá is your trusted partner in achieving regulatory clarity and commercial success. Where do you want to go next? Let’s go beyond, together.
TrialAssure
TrialAssure® delivers AI Enabled, Human Driven™ solutions for data, document, and image anonymization, medical writing, and clinical trial transparency. With this approach, we help life sciences be efficient, enhance disclosure, and protect patient privacy. Please reach out if you are looking for an AI-enablement partner.
TaiMed Biologics
TaiMed Biologics, founded in 2007, is a leading biopharmaceutical developer and manufacturer in Taiwan. We have extensive monoclonal antibodies (mAb) development and manufacturing experiences and have successfully developed and commercially launched the first and only mAb for HIV treatment in the US and Europe (Brand name: Trogarzo®). We are proud to offer Contract Development and Manufacturing Organization (CDMO) services for biopharmaceutical companies to propel your important monoclonal antibody molecules from development to market launch. | TaiMed Biologics & Orient EuroPharma — Your Trusted Partners in Biologics and CDMO Services TaiMed Biologics (TaiMed) is a leading biopharmaceutical company specializing in the development and manufacturing of innovative biologics, with a strong focus on anti-HIV therapies. Our Key Strengths Include: – First-in-Class Innovation: Developer of Trogarzo® (ibalizumab), the world’s first long-acting monoclonal antibody for HIV, approved by the US FDA and EMA in 2018 and 2019. – Next-Gen HIV Therapies: Advancing long-acting monoclonal antibodies for HIV treatment and prevention. – Clinical-Stage Leadership: Leading candidate TMB-365/380 received Fast Track Designation from the US FDA in 2023 and has successfully completed Phase 2a, showing promising potential as a more confirming and durable HIV therapy. – Partnering Opportunities: Actively seeking global licensing and co-development partnerships with companies focused on HIV therapy. – CDMO Services: Leveraging decades of antibody development experience, TaiMed now offers end-to-end CDMO solutions, from early-stage development through to commercial manufacturing. This year, TaiMed is proud to co-exhibit with our long-term partner, Orient EuroPharma (OEP), to present integrated, high-quality biomanufacturing solutions that meet global standards. About Orient EuroPharma (OEP) Founded in 1982, Orient EuroPharma (OEP) is a Taiwan-based multinational pharmaceutical company specializing in prescription medicines, nutricare, and anti-aging products. OEP also offers comprehensive CDMO services, providing expertise from formulation development to commercial-scale finished product manufacturing. OEP’s CDMO capabilities include: – Formulation Development: Expertise in controlled-release formulations – Oral Dosage Manufacturing: Tablet, Capsule (granule/pellets/semi-solid/liquid filling) – Injectable Manufacturing: Liquid and lyophilized vials for high potency, cytotoxic and non-cytotoxic product Why Partner with OEP? – Regulatory Excellence: 15+ successful IND submissions in the U.S., China, and Taiwan; NDA projects ongoing – U.S.-Based R&D (San Diego Lab): Local formulation development & small-scale batch production for faster collaboration – Advanced Capsule Technology: Specialized in semisolid/liquid filling and banding for enhanced drug stability -Flexible Manufacturing Scale: Seamless transition from small-batch IND to large-scale NDA production – Quality Certification: Facilities certified by US FDA, PIC/S GMP, TGA, and MHRA With a strong track record of innovation, regulatory success, and manufacturing quality, TaiMed and OEP together offer a powerful CDMO partnership to support your drug development and commercialization goals. Visit us at our booth to explore collaborative opportunities!
Stämm
Stämm is an international biotechnology company that is revolutionizing the way biomanufacturing is done. Founded in 2016, it’s now based in the United States and has offices and labs in Argentina and Switzerland. The company offers advanced solutions for automated, continuous, and improved biologics & cell therapies production with a wide range of solutions that stem from their core solution, the Bioprocessor, to cell line development and an AI transomics platform. Stämm’s mission is to make bioprocesses easy, scalable, sustainable and repeatable inspired by nature’s solutions, unleashing the full potential of biotechnology and thus freeing their partners to focus on the disruptive discoveries that make an impact in people’s lives. The company is committed to providing the best possible solutions to accelerate life-changing therapies through flexible, future-ready facilities that meet the evolving needs of its clients and improve global health. Products & Services Stämm’s products and services are structured in three segments: 1. Biomanufacturing: Stämm’s core solution is a continuous, bubble-free Bioprocessor, a biomanufacturing platform with a novel 3D printed bioreactor that enhances yields, reduces costs, and minimizes footprint and energy consumption. Stämm’s approach enables a scalable,energy-efficient solution that provides an ideal cell growth environment. 2. Bio AI: Stämm is developing a transomics platform that leverages in-silico methods through their Multi-omic Network Atlas (MoNA™) allowing to map the biomolecular behaviour of cells with its experimental ambient conditions. With MoNA, biotechnologists and molecular biologists will be able to reduce the uncertainty and risk during wet-lab assay design, execution and interpretation. Therefore achieving high precision biomolecular decision-making. 3.Bioenegineering: Stämm is developing state-of-the-art devices for Cell Line Development with automated cell engineering, clone outgrowth & screening for production of biologics. This is being done through a Bioengineering Platform, an engineering and sorting platform powered by a high-throughput automated system to streamline your workflow and a Clone Selection Platform, a specialized solution that automates clone selection and screening, monitoring the process to optimize your pipeline. Stämm’s is committed to providing a bio-innovative perspective capable of tackling the entire biomanufacturing pipeline